<?xml version="1.0" encoding="UTF-8"?>
<ref id="cam41388-bib-0009">
 <label>9</label>
 <mixed-citation publication-type="journal" id="cam41388-cit-0009">
  <string-name>
   <surname>Holmes</surname>, 
   <given-names>F. A.</given-names>
  </string-name>, 
  <string-name>
   <given-names>J. A.</given-names>
   <surname>O'Shaughnessy</surname>
  </string-name>, 
  <string-name>
   <given-names>S.</given-names>
   <surname>Vukelja</surname>
  </string-name>, 
  <string-name>
   <given-names>S. E.</given-names>
   <surname>Jones</surname>
  </string-name>, 
  <string-name>
   <given-names>J.</given-names>
   <surname>Shogan</surname>
  </string-name>, 
  <string-name>
   <given-names>M.</given-names>
   <surname>Savin</surname>
  </string-name>, et al. 
  <year>2002</year>
  <article-title>Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high‐risk stage II or stage III/IV breast cancer</article-title>. 
  <source>J. Clin. Oncol.</source>
  <volume>20</volume>:
  <fpage>727</fpage>–
  <lpage>731</lpage>.
  <pub-id pub-id-type="pmid">11821454</pub-id>
 </mixed-citation>
</ref>
